<p>Sarepta Therapeutics, Inc. (NASDAQ:SRPT - 获取免费报告) 的股价在周二的午盘交易中上涨了 3.5%。该股交易最高达到 $21.63，最后交易价格为 $21.9690。在交易中，共成交了 80,512 股，较平均交易量 5,986,445 股下降了 99%。该股此前收盘价为 $21.23。</p>
<p>获取 <strong>Sarepta Therapeutics</strong> 的提醒：</p>
<h2>分析师升级与降级</h2>
<ul>
<li>Sarepta 在 2025 年面临严峻挑战——分析师仍然预测 179% 的上涨空间</li>
</ul>
<p>SRPT 一直是多份研究分析报告的主题。华尔街禅在 11 月 8 日的研究报告中将 Sarepta Therapeutics 的股票评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。美国银行在 10 月 22 日的报告中将 Sarepta Therapeutics 的目标价从 $16.00 上调至 $18.00，并给予该公司 &#34;表现不佳&#34; 的评级。BMO Capital Markets 在 9 月 22 日的研究报告中将 Sarepta Therapeutics 的评级从 &#34;市场表现&#34; 上调至 &#34;跑赢大盘&#34;，并设定了 $50.00 的目标价。古根海姆在 11 月 5 日的研究报告中将 Sarepta Therapeutics 的目标价从 $22.00 下调至 $19.00，并给予该公司 &#34;买入&#34; 的评级。最后，Leerink Partners 在 9 月 9 日的研究报告中将 Sarepta Therapeutics 的目标价从 $12.00 上调至 $15.00，并给予该公司 &#34;市场表现&#34; 的评级。九位分析师对该股给予了买入评级，十五位给予了持有评级，六位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;持有&#34;，平均目标价为 $33.68。</p>
<p><strong>查看我们最新的 SRPT 股票分析</strong></p>
<h2>Sarepta Therapeutics 股价上涨 3.1%</h2>
<ul>
<li>Sarepta 因致死事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
<p>该公司的债务与股本比率为 0.78，速动比率为 1.79，流动比率为 2.95。该公司的 50 日移动平均价格为 $20.74，200 日移动平均价格为 $20.14。该公司的市值为 22.9 亿美元，市盈率为 -7.29，贝塔值为 0.54。</p>
<p>Sarepta Therapeutics (NASDAQ:SRPT - 获取免费报告) 最近在 11 月 3 日公布了季度财报。这家生物技术公司报告的季度每股收益为 ($0.13)，低于市场共识预期的 $0.02，差距为 ($0.15)。该公司在本季度的收入为 $3.9936 亿，低于分析师预期的 $3.3151 亿。Sarepta Therapeutics 的净利润率为 -11.25%，股本回报率为 -4.85%。与去年同期相比，Sarepta Therapeutics 的季度收入下降了 14.5%。在去年同期，该公司每股收益为 $0.62。研究分析师平均预测 Sarepta Therapeutics, Inc. 在当前年度将发布 2.67 的每股收益。</p>
<h2>内部人士买卖</h2>
<ul>
<li>制药行业抛售：RSI 指标显示的 3 只股票你不应忽视</li>
</ul>
<p>在其他 Sarepta Therapeutics 的新闻中，首席运营官 Ian Michael Estepan 于 12 月 16 日出售了 13,187 股该股票，交易价格为每股平均 $22.31，总价值为 $294,201.97。交易后，首席运营官持有该公司 193,300 股股票，价值约为 $4,312,523。这代表其持股比例下降了 6.39%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。公司内部人士持有该公司 7.60% 的股份。</p>
<h2>对 Sarepta Therapeutics 的对冲基金看法</h2>
<p>几家大型投资者最近调整了对该股票的持有。iSAM Funds UK Ltd 在第三季度新建了约 $25,000 的 Sarepta Therapeutics 持仓。Ancora Advisors LLC 在第三季度将其在 Sarepta Therapeutics 的持仓增加了 200.0%。Ancora Advisors LLC 目前持有 1,500 股该生物技术公司的股票，价值 $29,000，此前在上个季度又购买了 1,000 股。Byrne Asset Management LLC 在第三季度新建了约 $33,000 的 Sarepta Therapeutics 持仓。Allworth Financial LP 在第三季度将其在 Sarepta Therapeutics 的持仓增加了 2,098.8%。Allworth Financial LP 目前持有 1,803 股该生物技术公司的股票，价值 $35,000，此前在上个季度又购买了 1,721 股。最后，Parallel Advisors LLC 在第三季度将其在 Sarepta Therapeutics 的持仓增加了 165.3%。Parallel Advisors LLC 目前持有 2,016 股该生物技术公司的股票，价值 $39,000，此前在上个季度又购买了 1,256 股。86.68% 的股票由机构投资者持有。</p>
<h2>Sarepta Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Sarepta Therapeutics, Inc 是一家生物制药公司，专注于为罕见的神经肌肉疾病发现和开发精准基因治疗。公司总部位于马萨诸塞州剑桥，Sarepta 的核心专长在于设计针对 RNA 的疗法和基因疗法，以解决潜在的基因突变。公司的使命是通过创新的治疗方式改变杜氏肌营养不良症 (DMD) 及相关疾病患者的治疗模式。</p>
<p>Sarepta 的商业产品包括几种已获得美国批准的外显子跳跃疗法。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票超过 Sarepta Therapeutics</li>
<li>请勿删除，请立即阅读</li>
<li>投资者提醒：微型 “$3 人工智能奇迹股票” 即将爆发</li>
<li>埃隆警告 “美国破产”。特朗普的计划在此。</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄然抛售股票——原因在这里。</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Sarepta Therapeutics 吗？</h2>
<p>在考虑 Sarepta Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sarepta Therapeutics 并不在名单上。</p>
<p>虽然 Sarepta Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Sarepta医疗

<p>Sarepta Therapeutics（纳斯达克代码：SRPT）股票在午盘交易中上涨了 3.5%，达到 21.9690 美元。尽管上涨，但交易量明显低于平均水平。分析师的评级意见不一，普遍持 “持有” 评级，平均目标价为 33.68 美元。近期有内部人士卖出股票和对冲基金活动的情况被提及。该公司报告了季度收入下降和负的每股收益，未能达到预期。Sarepta 专注于基因药物的开发</p>

<p>Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report)'s stock price shot up 3.5% during mid-day trading on Tuesday . The stock traded as high as $21.63 and last traded at $21.9690. 80,512 shares changed hands during trading, a decline of 99% from the average session volume of 5,986,445 shares. The stock had previously closed at $21.23.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc. (NASDAQ:SRPT - 获取免费报告) 的股价在周二的午盘交易中上涨了 3.5%。该股交易最高达到 $21.63，最后交易价格为 $21.9690。在交易中，共成交了 80,512 股，较平均交易量 5,986,445 股下降了 99%。该股此前收盘价为 $21.23。</p>
</div><p>Get <strong>Sarepta Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sarepta Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级与降级</h2>
</div><ul>
<li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 在 2025 年面临严峻挑战——分析师仍然预测 179% 的上涨空间</li>
</ul>
</div><p>SRPT has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of Sarepta Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 8th. Bank of America boosted their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company an &#34;underperform&#34; rating in a report on Wednesday, October 22nd. BMO Capital Markets raised Sarepta Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $50.00 target price on the stock in a research report on Monday, September 22nd. Guggenheim lowered their price target on Sarepta Therapeutics from $22.00 to $19.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, November 5th. Finally, Leerink Partners raised their price objective on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the company a &#34;market perform&#34; rating in a research report on Tuesday, September 9th. Nine analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and an average price target of $33.68.</p>
<div class="lb-trans"><p>SRPT 一直是多份研究分析报告的主题。华尔街禅在 11 月 8 日的研究报告中将 Sarepta Therapeutics 的股票评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。美国银行在 10 月 22 日的报告中将 Sarepta Therapeutics 的目标价从 $16.00 上调至 $18.00，并给予该公司 &#34;表现不佳&#34; 的评级。BMO Capital Markets 在 9 月 22 日的研究报告中将 Sarepta Therapeutics 的评级从 &#34;市场表现&#34; 上调至 &#34;跑赢大盘&#34;，并设定了 $50.00 的目标价。古根海姆在 11 月 5 日的研究报告中将 Sarepta Therapeutics 的目标价从 $22.00 下调至 $19.00，并给予该公司 &#34;买入&#34; 的评级。最后，Leerink Partners 在 9 月 9 日的研究报告中将 Sarepta Therapeutics 的目标价从 $12.00 上调至 $15.00，并给予该公司 &#34;市场表现&#34; 的评级。九位分析师对该股给予了买入评级，十五位给予了持有评级，六位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;持有&#34;，平均目标价为 $33.68。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on SRPT</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 SRPT 股票分析</strong></p>
</div><h2>Sarepta Therapeutics Trading Up 3.1%</h2>
<div class="lb-trans"><h2>Sarepta Therapeutics 股价上涨 3.1%</h2>
</div><ul>
<li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 因致死事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
</div><p>The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95. The business's 50 day moving average price is $20.74 and its 200-day moving average price is $20.14. The company has a market cap of $2.29 billion, a price-to-earnings ratio of -7.29 and a beta of 0.54.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 0.78，速动比率为 1.79，流动比率为 2.95。该公司的 50 日移动平均价格为 $20.74，200 日移动平均价格为 $20.14。该公司的市值为 22.9 亿美元，市盈率为 -7.29，贝塔值为 0.54。</p>
</div><p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). The company had revenue of $399.36 million during the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. Sarepta Therapeutics's quarterly revenue was down 14.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.62 EPS. On average, research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.</p>
<div class="lb-trans"><p>Sarepta Therapeutics (NASDAQ:SRPT - 获取免费报告) 最近在 11 月 3 日公布了季度财报。这家生物技术公司报告的季度每股收益为 ($0.13)，低于市场共识预期的 $0.02，差距为 ($0.15)。该公司在本季度的收入为 $3.9936 亿，低于分析师预期的 $3.3151 亿。Sarepta Therapeutics 的净利润率为 -11.25%，股本回报率为 -4.85%。与去年同期相比，Sarepta Therapeutics 的季度收入下降了 14.5%。在去年同期，该公司每股收益为 $0.62。研究分析师平均预测 Sarepta Therapeutics, Inc. 在当前年度将发布 2.67 的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><ul>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>制药行业抛售：RSI 指标显示的 3 只股票你不应忽视</li>
</ul>
</div><p>In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer owned 193,300 shares of the company's stock, valued at approximately $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 7.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Sarepta Therapeutics 的新闻中，首席运营官 Ian Michael Estepan 于 12 月 16 日出售了 13,187 股该股票，交易价格为每股平均 $22.31，总价值为 $294,201.97。交易后，首席运营官持有该公司 193,300 股股票，价值约为 $4,312,523。这代表其持股比例下降了 6.39%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。公司内部人士持有该公司 7.60% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Sarepta Therapeutics</h2>
<div class="lb-trans"><h2>对 Sarepta Therapeutics 的对冲基金看法</h2>
</div><p>Several large investors have recently modified their holdings of the stock. iSAM Funds UK Ltd acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at about $25,000. Ancora Advisors LLC grew its position in shares of Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 1,000 shares during the last quarter. Byrne Asset Management LLC acquired a new position in Sarepta Therapeutics during the 3rd quarter worth approximately $33,000. Allworth Financial LP lifted its stake in Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 1,721 shares during the last quarter. Finally, Parallel Advisors LLC boosted its position in Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company's stock valued at $39,000 after buying an additional 1,256 shares in the last quarter. 86.68% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家大型投资者最近调整了对该股票的持有。iSAM Funds UK Ltd 在第三季度新建了约 $25,000 的 Sarepta Therapeutics 持仓。Ancora Advisors LLC 在第三季度将其在 Sarepta Therapeutics 的持仓增加了 200.0%。Ancora Advisors LLC 目前持有 1,500 股该生物技术公司的股票，价值 $29,000，此前在上个季度又购买了 1,000 股。Byrne Asset Management LLC 在第三季度新建了约 $33,000 的 Sarepta Therapeutics 持仓。Allworth Financial LP 在第三季度将其在 Sarepta Therapeutics 的持仓增加了 2,098.8%。Allworth Financial LP 目前持有 1,803 股该生物技术公司的股票，价值 $35,000，此前在上个季度又购买了 1,721 股。最后，Parallel Advisors LLC 在第三季度将其在 Sarepta Therapeutics 的持仓增加了 165.3%。Parallel Advisors LLC 目前持有 2,016 股该生物技术公司的股票，价值 $39,000，此前在上个季度又购买了 1,256 股。86.68% 的股票由机构投资者持有。</p>
</div><h2>Sarepta Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Sarepta Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc 是一家生物制药公司，专注于为罕见的神经肌肉疾病发现和开发精准基因治疗。公司总部位于马萨诸塞州剑桥，Sarepta 的核心专长在于设计针对 RNA 的疗法和基因疗法，以解决潜在的基因突变。公司的使命是通过创新的治疗方式改变杜氏肌营养不良症 (DMD) 及相关疾病患者的治疗模式。</p>
</div><p>Sarepta's commercial products include several exon-skipping therapies approved by the U.S.</p>
<div class="lb-trans"><p>Sarepta 的商业产品包括几种已获得美国批准的外显子跳跃疗法。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Sarepta Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Sarepta Therapeutics</li>
<li>请勿删除，请立即阅读</li>
<li>投资者提醒：微型 “$3 人工智能奇迹股票” 即将爆发</li>
<li>埃隆警告 “美国破产”。特朗普的计划在此。</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄然抛售股票——原因在这里。</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Sarepta Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sarepta Therapeutics 吗？</h2>
</div><p>Before you consider Sarepta Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Sarepta Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sarepta Therapeutics 并不在名单上。</p>
</div><p>While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sarepta Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Sarepta Therapeutics（纳斯达克代码：SRPT）股价上涨 3.5% - 这是怎么回事